Of all the new products helping Roche transition away from its old blockbuster portfolio, multiple sclerosis drug Ocrevus (ocrelizumab) is one of the biggest contributors.
Now other companies with similar products in development are trying to get in on the act, and data for these are due to be presented at the upcoming European Committee for Treatment and Research in